Abstract. We investigated the effects of bortezomib (PS-341) and immunomodulatory thalidomide analogs (immunomodulatory compounds; CC-4047, CC-6032, and CC-5013, or lenalidomide) on osteoblast and osteoclast differentiation in vitro using human mesenchymal stem cells (hMSC) to commit to osteoprogenitor cells and peripheral blood mononuclear cells (PBMCs) isolated from healthy donors, respectively. First, the concentration of bortezomib for an anti-myeloma effect was more than 1.0 nM in myeloma cells of multiple myeloma (MM) patients and more than 2.5 nM in myeloma cell lines. In contrast, anti-myeloma effects of immunomodulatory compounds on myeloma cells differed among myeloma cells and these compounds themselves. Subsequently, these agents (bortezomib; 0.5-5.0 nM, immunomodulatory compounds; 10 μM) were added to the osteoprogenitor cell culture media or the media for osteoclast differentiation. Low bortezomib concentrations (0.5 and 1.0 nM) increased ALP activity, and the delayed addition of bortezomib further increased ALP activity. Mineralized nodular formation with <2.5 nM bortezomib was not impaired. BMP2 expression on osteoprogenitor cells was found to increase in a time-dependent manner irrespective of treatment with bortezomib. On the other hand, the anti-osteoclast effect with low bortezomib concentration (≤2.5 nM) depended on MM patients. In contrast, immunomodulatory compounds at 10 μM showed an anti-osteoclast effect without cytotoxicity to osteoblast differentiation, at which dose myeloma cells underwent apoptosis. These findings might improve the treatment strategy for MM patients without damaging BM stromal cells by combining bortezomib with immunomodulatory compounds.

Introduction

Bone disease (BD) is a frequent characteristic of multiple myeloma (MM) and leads to severe clinical complications. The severity of BD correlates with the tumor burden and is one of the major parameters in the Durie and Salmon clinical staging system (1). BD in MM is due not only to the activation of osteoclasts but also to the impairment of osteoblast differentiation. Therefore, osteoclast-activating factors (OAF), such as interleukin-1β (IL-1β) (2), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β produced by myeloma cells (3), or receptor activator of NF-κB ligand (RANKL) expressed on stromal cells contacted with myeloma cells (4,5), play key roles in the development activation of osteoclasts in MM. On the other hand, overexpression of the Wnt signaling antagonists dickkopf1 (DKK1) and FRZB (secreted Frizzled-related protein 2, sFRP-2) correlates with MM-related bone disease (6,7). This combination of bone destruction and impairment of bone restoration is thought to be the cause of BD in MM.

Treatment for MM using new drugs, such as bortezomib (PS-341), thalidomide, and lenalidomide, has improved overall survival (OS). Interestingly, some reports have shown high serum bone-specific alkaline phosphatase levels after bortezomib-combined therapy in MM patients (8,9), and administration of proteasome inhibitor induced bone formation accompanied with the expression of bone morphogenetic protein-2 (BMP-2) in mice (10). However, the effect of bortezomib on osteoclast differentiation and the effects of immunomodulatory compounds on osteoclast or osteoblast differentiation remain unknown.

Here we analyzed the effects of these new drugs, bortezomib (PS-341), thalidomide, and lenalidomide, on osteoclast and osteoblast differentiation in vitro.
Materials and methods

Reagents. Bortezomib (PS-341) and immunomodulatory thalidomide analogs (immunomodulatory compounds; CC-4047, CC-6032 and CC-5013, or lenalidomide) were kindly donated by Millennium Pharmaceuticals Inc. (Cambridge, MA, USA) and Celgene Corporation (Warren, NJ, USA), respectively. They were dissolved in dimethylsulfoxide (DMSO) and stored at -20°C. The final concentration of DMSO in all experiments was <0.1%.

Myeloma cell purification. Bone marrow (BM) mononuclear cells (MNCs) were isolated from fresh BM aspirates as described previously (11). Plasma (myeloma) cells were purified using MACS CD138 Micro Beads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer’s instructions. Written informed consent was obtained from all patients.

Cell proliferation assay. To evaluate the cytotoxic effects of bortezomib and immunomodulatory compounds on myeloma cell lines (U266, KMS21BM, and RPMI8226) and purified myeloma cells of MM patients, a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) was used according to the manufacturer’s instructions. This assay is based on colorimetric quantification of NADH (12). Cells were suspended in media according to their purpose. Media containing bortezomib (PS-341) (10-1.0 nM) were replenished twice a week, and immunomodulatory compounds (CC-4047, CC-6032, CC-5013, or lenalidomide) were added every day. As controls for bortezomib and immunomodulatory compounds, media were supplemented with <0.1% DMSO.

Osteoclast differentiation from osteoclast precursors or human bone marrow cells. Peripheral blood mononuclear cells (PBMCs) were isolated from 2 healthy donors as described previously (11). Subsequently, we deleted adherent cells by incubation in flasks for 4 h. Non-adherent PBMCs were seeded on Lab Tec-Chamber slides (Nalge Nunc International, Rochester, NY, USA) and incubated in osteoclast precursor growth medium containing fetal bovine serum (FBS), L-glutamine, penicillin-streptomycin (SankoJunyaku Co.), and recombinant human M-CSF (rhM-CSF) (10 ng/ml) (R&D, Minneapolis, MN, USA) for 2 days. Subsequently, we cultured the cells according to the method of Takayanagi et al (13). Briefly, cells were cultured in α-MEM (Gibco, Invitrogen, Tokyo, Japan) containing 10% FCS, penicillin-streptomycin, rhM-CSF (10 ng/ml), and recombinant human RANKL (rhRANKL) (50 ng/ml) (R&D). To evaluate the effect of bortezomib (PS-341) and immunomodulatory compounds (CC-4047, CC-6032, CC-5013, or lenalidomide) on osteoclast differentiation, these components were added to the culture media according to purpose. Media containing bortezomib (PS-341) (10-1.0 nM) were replenished twice a week, and immunomodulatory compounds (10 μM) were added every day. As a control for PS-341 and immunomodulatory compounds, the media were supplemented with <0.1% DMSO.

TRAP staining. TRAP staining was performed at day 14 using a TRAP staining kit (Sigma-Aldrich, Saint Louis, MO, USA) according to the manufacturer’s instructions. We counted TRAP* multinucleated cells (>2) as mature osteoclasts. Examinations were performed in duplicate.

Bone morphogenetic protein 2 (BMP2) expression by real-time quantitative reverse-transcriptase-polymerase chain reaction (RQ-PCR). To evaluate the induction of BMP2 by bortezomib (PS-341), hMSCs were obtained from Sanko Junyaku Co. and cultured as described above. After reaching 90% confluence, the medium was changed as described above. To evaluate whether bortezomib (PS-341) induces
BMP2 and whether this effect depends on the time of addition of bortezomib to the culture media or the duration of culture, we added 1.0 nM bortezomib (PS-341) to media at the same time as the initiation of osteoprogenitor cell culture or at 5 days after culture in this medium. Cells were incubated for 12 or 60 h, then detached by 0.5% Trypsin-EDTA treatment and washed twice with ice-cold phosphate-buffered saline (PBS). Subsequently, total RNA was extracted using an RNeasy Mini kit (Qiagen, Tokyo, Japan) according to the manufacturer's instructions. As a control, total RNA was extracted from mesenchymal stem cells cultured in MSCBM. cDNAs were made using a first-strand cDNA synthesis kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to the manufacturer's instructions. RQ-PCR reactions were performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Primers and probes were as follows: BMP2 probe, 5'-FAM-ATCTGAACTACACTAATC-MGB-3', BMP2 forward, 5'-GCCCTTTTTCCTGCTCTGAT-3', and BMP2 reverse, 5'-TGACCAACGTCTGAACAATGG-3'. PCRs for GAPDH were performed with a ready-made mix of reagents from Applied Biosystems (item no. 4326317E).

### Statistical analysis

The significance of the association of ALP activities or the number of TRAP-positive cells under different culture conditions was assessed with the unpaired t-test. The level of significant difference by the unpaired t-test was set at p<0.05.

### Results

**Effects of bortezomib (PS-341) on apoptosis in MM cells.** We first tried to determine the working concentration of bortezomib in our culture system of osteoblast and osteoclast differentiation by treatment of MM cell lines (KMS21BM, U266, and RPMI8226) with bortezomib (0-5.0 nM). As seen in Fig. 1, treatment of MM cells with 5 nM bortezomib for 24 h induced a significant (p<0.05) decrease of viability in these cell lines. Low bortezomib concentrations of not more than 2.5 nM did not show any apoptotic effect on these MM cell lines. On the other hand, treatment of patient myeloma cells with 2.5 nM bortezomib for 24 h induced a significant (p<0.05) decrease of viability. This result led us to use a concentration of bortezomib of ≤5.0 nM for analysis of the effects on osteoblast and osteoclast differentiation.

**Effects of immunomodulatory thalidomide analogs (immunomodulatory compounds: CC-4047, CC-6032, CC-5013 or lenalidomide) on apoptosis in MM cells.** Next we tried to determine the working concentrations of immunomodulatory compounds as mentioned in Fig. 1. As shown in Fig. 2, MM cells were treated with the immunomodulatory compounds (0-10 μM) for 72 h. Treatment of U266 with 1 μM immunomodulatory compounds (all compounds) induced a significant (p<0.05) decrease of viability; however, treatment with 5.0 and 10 μM did not induce any further decrease (Fig. 2A). Treatment of KMS21BM with CC-6032 and CC-5013 induced a significant (p<0.05) decrease of viability in a dose-dependent manner, and treatment with 1 μM CC-4047 induced a significant (p<0.05) decrease of viability. However, treatment with 5.0 and 10 μM CC-4047 did not induce a further decrease (Fig. 2B). Furthermore, treatment of RPMI8226 with CC-6032 showed a dose-dependent anti-myeloma cell effect; however, treatment with CC-5013 did not show an anti-myeloma cell effect at any concentration against RPMI8226, and treatment with CC-4047 induced a significant (p<0.05) decrease of viability only at 10 μM (Fig. 2C). Treatment of patient myeloma cells with 1 M CC-6032 and CC-5013 induced a significant (p<0.05) decrease of viability; however, treatment with CC-5013 did not show an anti-myeloma cell effect at any concentration against RPMI8226, and treatment with CC-4047 induced a significant (p<0.05) decrease of viability only at 10 μM (Fig. 2C). Treatment of patient myeloma cells with 1 M CC-6032 and CC-5013 induced a significant (p<0.05) decrease of viability; however, treatment with CC-4047 did not induce a significant decrease of viability at 1 μM, and treatment with 5.0 and 10 μM of these agents did not induce a further decrease (Fig. 2D). Therefore, the apoptotic effects of immunomodulatory compounds on myeloma cells differed among myeloma cells and immunomodulatory compounds themselves.

**Low bortezomib (PS-341) concentration promotes osteoblast differentiation.** Recent reports showing high serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in MM patients led us to expect that a low concentration of bortezomib would support osteoblast differentiation. Here we used a human mesenchymal stem cell (hMSC) culture system to analyze whether bortezomib promotes osteoprogenitor cell differentiation according to
concentration. The fate of commitment from hMSC depends on the medium, so we used medium for osteoprogenitor cell culture after reaching 90% confluence. First, we added bortezomib (0.5-10 nM) to the media from the initiation of osteoprogenitor cell culture. As shown in Fig. 3A, ALP activity was significantly different and dose-dependent; 5.0 nM bortezomib showing an anti-myeloma cell effect also suppressed ALP activity in osteoprogenitor cells, <2.5 nM bortezomib did not suppress it compared with the control. The effective concentration of bortezomib in sera of MM patients is not well known. The IC50 (nM) was reported to be 2.5-30 nM in myeloma cells of MM patients (14). Of note, ALP activity in 0.5 nM bortezomib was significantly higher (p<0.05) than that of the control apart from the anti-myeloma cell effect; however, there was no difference in ALP activity between 1.0 and 2.5 nM bortezomib and the control. Next, we added bortezomib (0.5-5.0 nM) to the media 5 days after the initiation of osteoprogenitor cell culture to investigate whether the initiation of bortezomib would affect the ALP activity. As shown in Fig. 3A, ALP activity was significantly (p<0.05) higher in culture medium with the addition of 5 days of delayed bortezomib except for the concentration of 0.5 nM, and there were no significant differences in ALP activity of osteoprogenitor cells cultured between 1.0 nM and 0.5 nM bortezomib. Therefore, these results showed that a low bortezomib concentration could promote osteoprogenitor cell differentiation and might be more effective for slightly matured osteoprogenitor cells than immature cells. Next, we investigated mineralized nodule formation by von Kossa staining at 42 days after the initiation of osteoprogenitor cell culture and bortezomib (1.0-10 nM). As shown in Fig. 3B, 10 nM bortezomib completely suppressed mineralized nodule formation; however, we detected mineralized nodule formation in osteoblasts incubated with 5.0 nM bortezomib, in which the anti-myeloma cell effect was confirmed in Fig. 1. and the mineralized nodule formation with 2.5 and 1.0 nM bortezomib seemed to be similar to that of the control. These results suggested that long culture might compensate for the difference in ALP activity according to the concentration of bortezomib in the early stage of osteoblast differentiation.

**Immunomodulatory thalidomide analogs (CC-4047, CC-6032, CC-5013) do not suppress osteoblast differentiation.** We investigated ALP activity in osteoprogenitor cells at day 16 by adding 10 μM of each immunomodulatory compound to media after the initiation of osteoprogenitor cell culture. The anti-myeloma cell effect in this concentration was confirmed in Fig. 2 and by a previous study (15). As shown in Fig. 4A, no immunomodulatory compounds suppressed ALP activity compared with the control at this concentration. Subsequently, we investigated mineralized nodule formation by von Kossa staining at day 42, and it was detected similarly in all osteoprogenitor cell cultures with immunomodulatory compounds compared with the control (Fig. 4B). These results suggested that immunomodulatory compounds would not suppress osteoblast differentiation.

**BMP2 expression in osteoprogenitor cells might be time-dependent in osteoprogenitor cell culture but independent of the treatment of bortezomib (PS-341).** We analyzed the expression of BMP2 in osteoprogenitor cells by adding 1.0 nM bortezomib in the early stage of osteoblast differentiation from MSCs since BMP2 is thought to have an autocrine effect on osteoblast differentiation (10) and to be an important factor in the early stage of osteogenic differentiation (16). We added 1.0 nM bortezomib to media at the same time as the initiation of osteoprogenitor cell culture or after culture for 5 days in these media. This concentration (1.0 nM) was
determined based on the result showing that both 1.0 and 0.5 nM bortezomib significantly increased ALP activity (Fig. 3B). Cells were incubated for 12 or 60 h after the addition of bortezomib to the culture medium for osteoblasts from initiation of the change of medium. The highest concentration of bortezomib was 5.0 nM since we confirmed that this concentration showed an anti-myeloma effect (Fig. 1). Then, we gradually decreased the concentration of bortezomib (5.0, 2.5, 1.0, and 0.5 nM) in the medium and analyzed ALP activity to compare with the control. The analysis of ALP activity between two different initiation days of bortezomib administration; white bars, bortezomib was added from initiation of the change of medium; and black bars, bortezomib was added from 5 days after the initiation of medium. Results are expressed as the means ± SEM of triplicate experiments. (B) von Kossa staining was performed at day 42 after the initiation of culture for osteoblast differentiation. Bortezomib was added from the initiation day. Bortezomib at 10 nM completely suppressed mineralized nodule formation and at 5.0 nM also suppressed mineralized nodule formation. Bortezomib at 2.5 nM showed similar mineralized nodule formation to the control.
dependent manner in osteoprogenitor cell culture medium, independent of treatment with bortezomib.

Both bortezomib (PS-341) and immunomodulatory thalidomide analogs suppress osteoclast differentiation. Next we investigated the effects of bortezomib and immunomodulatory compounds on osteoclast differentiation by TRAP staining. First, we cultured monocytes from PB in medium containing recombinant human M-CSF for 2 days. Subsequently, we cultured the cells with rhM-CSF, rhRANKL, and bortezomib or immunomodulatory compounds. TRAP staining was performed at day 14. As shown in Fig. 6A, in culture using PBMCs from one healthy donor, 10 and 5.0 nM bortezomib suppressed osteoclast differentiation, but there was no significant difference in TRAP-positive cells with 2.5 and 1.0 nM bortezomib compared with the control. However, in culture using another healthy donor, even 1.0 nM bortezomib suppressed osteoclast differentiation. On the other hand, the effects of immunomodulatory compounds on osteoclast differentiation showed similar results in two healthy donors; each compound suppressed osteoclast differentiation in 10 μM (Fig. 6B). Therefore, both bortezomib and immunomodulatory compounds showed suppressive effects on osteoclast differentiation at anti-myeloma cell effect concentrations of 5.0 and 10 μM, respectively.

Discussion

Recent new drugs such as proteasome inhibitor, bortezomib (PS-341) and lenalidomide are improving the complete response rate and OS for patients with MM (17-24), and recent studies revealed the efficacy of immunomodulatory compounds for drug-resistant myeloma cells (15,25-27). First, regarding the proteasome inhibitor, bortezomib, some reports have shown an increase of ALP activity after bortezomib administration (8,9,28), and one study in mice revealed that treatment with proteasome inhibitors promoted bone formation and increased BMP2 expression (10). On the other hand, an up-to-date study revealed inhibition of osteoclastogenesis by bortezomib (29). As for immunomodulatory thalidomide analogs, CC-4047 was reported to inhibit osteoclast formation by down-regulation of PU.1 (30), and Revlimid (CC-5013, lenalidomide) was thought to inhibit osteoclast growth and survival (Breitkreutz et al, ASCO, abs. 7606, 2006). Although immunomodulatory compounds are known to inhibit interaction between myeloma cells and BM stromal cells (osteoblasts) (31), the direct effect of immunomodulatory compounds on osteoblasts is not clear.

For the investigation of osteoclast differentiation, we used an hMSC culture system. Although recent studies pointed out the abnormal features of MSCs in MM patients (32,33), we thought that the BM milieu with the proliferation of myeloma cells produced abnormal characteristics of MSCs. We added 0.5-10 nM bortezomib to an osteoprogenitor cell culture based on data showing the range of IC50 to be 2.5-30 nM when bortezomib was administered to patients with MM (14) and our preliminary result showed that 10 nM bortezomib was too cytotoxic for osteoprogenitor cells (data not shown). Subsequently, we changed the concentration or the time of bortezomib addition to the culture media to investigate how...
they would work. In contrast, we decided to add 10 μM of each immunomodulatory compound to the medium for osteoprogenitor cell culture because this concentration showed a cytotoxic effect on myeloma cells (Fig. 1B), as in the study by Hideshima et al (15). Here we determined ALP activity as an indicator of a differentiation marker of osteoblasts from the early to mature phase, and mineralized nodule formation detected by von Kossa staining as an indicator of ultimately differentiated osteoblasts.

First, 5.0 nM bortezomib showing clear cytotoxicity to myeloma cell lines suppressed ALP activity, and 2.5 nM bortezomib also suppressed ALP activity when it was added to the media from the initiation of osteoprogenitor cell culture medium; however, this concentration did not suppress ALP activity compared with the control when it was added 5 days after the initiation of this medium. Furthermore, ALP activity increased according to the decrease of bortezomib concentration (1.0 and 0.5 nM). It was doubtful whether these low concentrations of bortezomib would show an anti-myeloma cell effect, and in fact these concentrations were not effective on myeloma cell lines or patient myeloma cells (Fig. 1). The result of the anti-myeloma cell effect of bortezomib requiring a high concentration seemed to be contradictory to the promotion of osteoblast differentiation by low concentration in clinical administration; however, 2.5 nM bortezomib induced apoptosis in primary myeloma cells and, considering that our cell proliferation assay was performed in 10% FCS, we expected that an effective bortezomib concentration in sera of MM patients could not be fixed. In contrast, von Kossa staining at day 42 after the initiation of osteoprogenitor cell culture showed mineralized nodule formation with 2.5 nM bortezomib; therefore, we could not state that 2.5 nM bortezomib suppressed osteoblast differentiation in the long term.

As for the expression of BMP2, the addition of bortezomib to media did not increase its expression, and BMP2 expression might depend on the duration of culture from the initiation of osteoprogenitor cell culture to RNA extraction. Considering that the recent study by Giuliano et al (34) showed that bortezomib significantly increased transcription factor Runx2/Cbfa1 activity by the ELISA-based method and immunostaining performed on BM biopsies, the expression of BMP2 protein should have been analyzed later by similar methods.

Next, the effective concentration of bortezomib to suppress osteoclast differentiation might differ among cases. In one healthy donor sample, <2.5 nM bortezomib did not suppress osteoclast differentiation; however, even 1.0 nM bortezomib suppressed it in another case, as well as in the result reported by von Metzler et al (29). Surprisingly, even 0.1 nM bortezomib suppressed osteoclast differentiation in their study, and we would suggest that a high concentration (5.0 nM) of bortezomib would certainly be effective in suppressing osteoclast differentiation. This concentration might be reasonable for the treatment of MM since it could be useful for both an anti-myeloma cell effect and anti-osteoclast differentiation. Considering the relationship between myeloma cells and osteoclasts, in which osteoclasts support the survival and proliferation of myeloma cells (35), treatment with bortezomib in MM patients could be useful and reasonable. Therefore, if there was no direct anti-myeloma effect with a low concentration of bortezomib, we could expect an indirect anti-myeloma effect through the suppression of osteoclast differentiation.

Osteoblast differentiation was not suppressed even in 10 μM immunomodulatory compounds, which showed strong cytotoxicity to myeloma cell lines (15), because ALP activity did not decrease and mineralized nodule formation was detected by von Kossa staining. On the other hand, we could expect a strong cytotoxic effect of immunomodulatory compounds on osteoclast differentiation.

In conclusion, it is expected that bortezomib in a range of concentrations would show both an anti-myeloma cell effect and promotion of bone formation in MM patients, and an anti-osteoclast effect at low concentrations in some cases. On the other hand, we could expect that immunomodulatory compounds would show both anti-myeloma cell and osteoclast effects at a concentration not cytotoxic to osteoblast differentiation. Therefore, we might improve the treatment strategy for MM patients without damage to BM stromal cells by combining bortezomib with immunomodulatory compounds such as lenalidomide.

Acknowledgments

We appreciate the help of H. Sumida, K. Yamamoto, N. Nakaj, S. Matsumoto, and R. Yamaguchi for their excellent technical or secretarial assistance.

References


